Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care
February 15, 2024 14:57 ET
|
Research and Markets
Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Recent advancements in cancer treatment and the...
MTG201 + Nivolumab Drug and Market Analysis 2023-2032: Sales Analytics, Clinical Assessment, SWOT Analysis, Emerging Competitors
January 30, 2024 10:50 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "MTG201 + nivolumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides...
Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032
December 14, 2023 10:08 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
China Nivolumab Market Market Report 2021: Sales Value Increased from CNY9.9 Million in 2018 to CNY 43.1 Million in 2020 - Forecast to 2025
June 02, 2021 04:33 ET
|
Research and Markets
Dublin, June 02, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Nivolumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to this market...
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
June 02, 2020 08:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
December 13, 2017 17:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the...